Thera-SAbDab

GUSELKUMAB

>   Structural Summary
TherapeuticGuselkumab
TargetIL23A
Heavy ChainEVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS
Light ChainQSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL
100% seqID Fv Structure4m6m [Fvs: HL], 4m6n [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)Active
Recorded Developmental TechnologyMorphoSys HuCAL Phage Display
INN Year Proposed2013
INN Year Recommended2014
Companies InvolvedJanssen Biotech, MorphoSys, Taiho Pharmaceutical
Conditions ApprovedErythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis, Psoriatic arthritis, Pustular psoriasis
Conditions ActiveCrohn's disease, Hidradenitis suppurativa, Ulcerative colitis, Familial adenomatous polyposis, Psoriasis, Giant cell arteritis, Lupus nephritis, Systemic scleroderma
Conditions DiscontinuedRheumatoid arthritis
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy